The Role of Para-Aortic Lymphadenectomy in the Surgical Staging of Women with Intermediate and High-Risk Endometrial Adenocarcinomas
Table 2
Disease-free survival analysis adjusting for the following variables: tumor histology, lymphovascular invasion, myometrial invasion, and number of para-aortic lymph nodes.
No recurrence
Recurrence
Age-adjusted HR (95% CI)
Fully adjusted* HR (95% CI)
Histology
Endometrioid/mixed
112 (61.5%)
52 (70.3%)
1.00
1.00
Clear cell
17 (9.3%)
7 (9.5%)
0.95 (0.42, 2.14)
1.33 (0.58, 3.05)
0.50
Papillary serous
53 (29.1%)
15 (20.3%)
0.64 (0.36, 1.15)
0.68 (0.37, 1.26)
0.23
Lymphovascular invasion
No
112 (67.1%)
23 (32.9%)
1.00
1.00
Yes
55 (32.9%)
47 (67.1%)
2.99 (1.82, 4.93)
1.67 (0.91, 3.07)
0.10
Myometrial invasion
No
121 (67.6%)
27 (38.0%)
1.00
1.00
Yes
58 (32.4%)
44 (62.0%)
2.76 (1.70, 4.45)
1.69 (0.93, 3.06)
0.08
Lymph nodes
PLN
111 (60.7%)
28 (37.8%)
1.00
1.00
PPALN 10*
56 (30.6%)
42 (56.8%)
2.16 (1.33, 3.52)
2.34 (1.36, 4.02)
0.002
PPALN 10**
16 (8.7%)
4 (5.4%)
1.06 (0.37, 3.01)
1.36 (0.44, 4.24)
0.59
PPALN patients with less than 10 para-aortic nodes dissected.
**PPALN patients with 10 or more dissected para-aortic nodes.
